Recorded live at HFSA 2025, hosts explore the evolving landscape of heart failure endpoints, focusing on the significance of oral diuretic intensification in outpatient care.
All content for Don't Miss a Beat is the property of HCPLive Cardiology and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Recorded live at HFSA 2025, hosts explore the evolving landscape of heart failure endpoints, focusing on the significance of oral diuretic intensification in outpatient care.
In this episode of Don’t Miss a Beat, Javed Butler, MD, joins hosts Muthiah Vaduganthan, MD, MPH, and Steve Greene, MD, for a breakdown of the EMPACT-MI trial, including primary results, secondary findings, how data from DAPA-MI and EMPACT-MI complement each other, and what is next for the SGLT2 inhibitor class.
Key Highlights:
00:00 - Intro
01:57 - Trial Design and Results
07:00 - Inclusion Criteria and Patient Characteristics
10:53 - Primary Results of EMPACT-MI
14:34 - Subgroup Analyses
15:27 - Implications for Post-MI Patient Population
19:53 - Takehome Messages for Care
23:39 - Kidney Outcomes in Post-MI Patient Population
Don't Miss a Beat
Recorded live at HFSA 2025, hosts explore the evolving landscape of heart failure endpoints, focusing on the significance of oral diuretic intensification in outpatient care.
